Concepedia

Debbie Davies

DD

Statistics

Publications

6

Citations

1.2K

H-Index

6

Active since

2011

Affiliations

Alexion Pharmaceuticals (United States)(Current)

Fondazione IRCCS Istituto Neurologico Carlo Besta

University of North Carolina at Chapel Hill

International University of Health and Welfare

Stanford University

Debbie Davies is an author at Alexion Pharmaceuticals (United States) specializing in medicine, myasthenia gravis pharmacotherapy, and anti-acetylcholine receptor antibodies.

Publications per year

2011–2020

6

Publications

6

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 800 citations

, , +6

The motor phenotype of Parkinson's disease in relation to age at onset

Mirdhu Wickremaratchi, Duleeka Knipe, B. S. D. Sastry et al. · Movement Disorders · 2011 · 156 citations

, , +14

Parkinson’s disease: summary of updated NICE guidance

G Rogers, Debbie Davies, Joshua Pink et al. · BMJ · 2017 · 114 citations · Full text

, , +13

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 79 citations · Full text

, , +9

Eculizumab improves fatigue in refractory generalized myasthenia gravis

Henning Andersen, Renato Mantegazza, Jing Jing Wang et al. · Quality of Life Research · 2019 · 56 citations · Full text

, , +14

1–5 of 6